Acorn Financial Advisory Services Inc. ADV Sells 1,029 Shares of DaVita Inc. (NYSE:DVA)

Acorn Financial Advisory Services Inc. ADV cut its position in DaVita Inc. (NYSE:DVAFree Report) by 23.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,400 shares of the company’s stock after selling 1,029 shares during the quarter. Acorn Financial Advisory Services Inc. ADV’s holdings in DaVita were worth $557,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of DVA. Blue Trust Inc. raised its stake in DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares in the last quarter. Family Firm Inc. purchased a new position in DaVita in the 2nd quarter worth $43,000. Versant Capital Management Inc lifted its stake in DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after purchasing an additional 155 shares during the last quarter. Friedenthal Financial purchased a new stake in DaVita during the second quarter valued at about $48,000. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of DaVita during the second quarter valued at approximately $68,000. 90.12% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

DVA has been the subject of a number of recent analyst reports. UBS Group upped their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. TD Cowen raised their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Barclays upped their price target on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Bank of America upped their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. Finally, Truist Financial boosted their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $161.80.

View Our Latest Analysis on DaVita

DaVita Stock Performance

NYSE DVA traded down $0.71 during trading hours on Friday, hitting $149.66. The company’s stock had a trading volume of 748,662 shares, compared to its average volume of 819,478. DaVita Inc. has a 12 month low of $82.79 and a 12 month high of $168.50. The company’s 50 day simple moving average is $157.15 and its two-hundred day simple moving average is $146.71. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The company has a market cap of $12.27 billion, a P/E ratio of 16.14, a price-to-earnings-growth ratio of 0.83 and a beta of 0.89.

DaVita (NYSE:DVAGet Free Report) last issued its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). The company had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.85 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Insider Activity at DaVita

In related news, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the sale, the chief financial officer now directly owns 111,481 shares in the company, valued at approximately $17,286,243.86. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 173,482 shares of company stock worth $27,387,069. 2.00% of the stock is owned by insiders.

DaVita Company Profile

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Further Reading

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVAFree Report).

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.